The European biotechnology market is projected to grow at a significant CAGR of 6.9% during the forecast period (2020-2026). Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term that is used to describe a number of different modern sequencing technologies such as Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent: Proton / PGM sequencing, SOLiD sequencing and so on. These recent technologies allow us to sequence DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing. Such technologies have therefore revolutionized the study of genomics and molecular biology. The advancements in NGS are driving the R&D programs across the region.
To Request a Sample of our Report on European Biotechnology Market: https://www.omrglobal.com/request-sample/european-biotechnology-market
The rising lifestyle-oriented diseases such as CVD, CHD, Cancer, infectious diseases and so on are creating demand for NGS for the R&D process. Technological advancements have led to the introduction of NGS platforms in cancer investigation. NGS allows massive parallel sequencing that affords maximal tumor genomic assessment. NGS approaches are different, and concern DNA and RNA analysis. In recent years, NGS technologies have played a vital role in understanding the altered genetic pathway involved in human cancer. The fact that NGS has a high likelihood of producing results of unknown significance that it has attracted the researchers to explore the cancer disease.
(Get 15% Discount on Buying this Report)
A full Report of European Biotechnology Market is Available at: https://www.omrglobal.com/industry-reports/european-biotechnology-market
European Biotechnology Market – Segmentation
By Type
- Healthcare
- Crop Production and Agriculture
- Industrial
- Natural Resources & Environment
- Others (Bioinformatics)
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
